House Speaker Paul Ryan (R-WI) yesterday discussed a potential compromise on the Creating and Restoring Equal Access to Equivalent Samples Act (S. 974/H.R. 2212), as part of congressional action to address high drug prices. “We’re working between the Commerce Committee and the Judiciary Committee on a compromise on what we call CREATES, which is getting the generics online faster after patents have expired, so I think there are things we can do in that area,” Ryan said, according to published reports, during an event hosted by a Washington, D.C. law firm. Among other provisions, the legislation would allow a generic drug manufacturer facing a sample-sharing delay tactic to bring an action in federal court for injunctive relief and allow a judge to award damages to deter future delaying conduct. Earlier this year, AHA and more than 40 organizations urged Congress to pass the legislation calling it “a narrowly targeted, bipartisan, pro-competition and market-based solution to these abuses that cost patients, job-creators and taxpayers billions of dollars each year.”

Headline
Rep. Randy Feenstra, R-Iowa, introduced the Rural Maternity Options for Medical Support Act on May 19. The bill would guarantee that beds used solely for labor…
Headline
The House Education and Workforce Committee May 21 unanimously passed the Transparency in Billing Act (H.R. 8684). The bill would require off-campus hospital…
Headline
The White House May 18 announced an expansion of TrumpRx.gov, which now features more than 600 generic drugs. The direct-to-consumer platform serves as a hub…
Headline
The Department of Health and Human Services yesterday announced an action plan on psychiatric prescribing, including efforts to initiate …
Headline
The AHA April 29 urged House and Senate appropriations committee leaders to fund health care programs that have been successful in improving access to care for…
Headline
The AHA submitted a statement for the record to the House Ways and Means Committee for its April 28 hearing with health system CEOs.In the statement, the AHA…